Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential intrahepatic integrated HBV DNA patterns between HBeAg-positive and HBeAg-negative chronic hepatitis B.

Gut·2026
Same author

Helicobacter pylori in Israel: real-life data from a large database on frequency of non-invasive testing, follow-up testing and risk factors for infection.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same author

Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.

Journal of hepatology·2025
Same author

Autoimmune-Like Hepatitis Following Hepatic Graft-Versus-Host Disease in an Allogenic Hematopoietic Cell Transplant Recipient.

Case reports in hepatology·2025
Same author

Impact of Universal Screening for HDV in HBV-Infected Patients on Chronic HDV Detection Rate in Israel.

Journal of viral hepatitis·2025
Same author

Editorial: Clinical Impact of Lipid Profile Change After DAA Treatment in CHC Patients-Authors' Reply.

Alimentary pharmacology & therapeutics·2025

Related Experiment Video

Updated: Oct 2, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.3K

Review article: hepatitis B-current and emerging therapies.

David Yardeni1, Marc G Ghany1

  • 1Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

Alimentary Pharmacology & Therapeutics
|February 28, 2022
PubMed
Summary

New hepatitis B virus (HBV) therapies aim for a functional cure, moving beyond current treatments that require long-term use and do not eliminate the virus. Research focuses on novel approaches to achieve sustained viral clearance.

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.8K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.4K

Related Experiment Videos

Last Updated: Oct 2, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.3K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.8K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.4K

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis B virus (HBV) infection impacts 290 million globally, causing nearly 900,000 deaths annually from liver cirrhosis and cancer.
  • Current treatments manage complications but are not curative, necessitating long-term administration and highlighting the need for finite curative therapies.

Purpose of the Study:

  • To review current and emerging treatment options for chronic hepatitis B.
  • To provide an up-to-date overview of therapeutic strategies for HBV.

Main Methods:

  • Searched PubMed, clinicaltrials.gov, major meeting abstracts, and pharmaceutical websites.
  • Identified publications and communications on existing and novel HBV therapies.

Main Results:

  • Approved therapies like peginterferon and nucleos(t)ide analogues rarely achieve functional cure (HBsAg loss) or complete cure (cccDNA and integrated HBV DNA clearance).
  • Emerging therapies target viral entry, cccDNA, transcription, core protein, HBsAg/polymerase release, and utilize novel immunological approaches, including therapeutic vaccination.

Conclusions:

  • Numerous novel therapeutic strategies are under investigation for chronic hepatitis B.
  • These emerging treatments hold promise for achieving a functional cure for HBV infection.